Syneron Bio completed a $150 million Series B financing.
- Amount
- $150M
- Stage
- Series B
- Announced
- 3 April 2026
- Leads
- an international life-science fund, Decheng Capital, CDH VGC
- Other investors
- a wholly owned subsidiary of the Abu Dhabi Investment Authority, True Light Capital, Qiming Venture Partners, BioTrack Capital, AstraZeneca, LAV, Sinovation Capital, 5Y Capital, GL Ventures
- Checked
- Amount and date checked against the press source